重组人促红细胞生成素治疗肿瘤化疗中贫血的临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:


Clinical study of the anemic management with rhEPO in malignancy patients receiving chemotherapy
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:研究重组人促红细胞生成素(rhEPO)对接受化疗的肿瘤患者提升血红蛋白的治疗效果-方法:151例肿瘤化疗患者随机分为三组-常规剂量组:rhEPO 10 000 U/次,皮下注射(s.c.),每周3次,持续8周;冲击治疗组:rhEPO 20 000 U,1 次/天,连用2天后,10 000 U,1 次/天,连用6天,随后同常规剂量组;对照组:不给予rhEPO,其他同治疗组-结果:经EPO治疗后,冲击组从第2周开始平均Hb水平较治疗前提高2.6 g/L(P = 0.000),与常规组相比,第2周时平均Hb水平提高2.9 g/L,但无明显统计学差异(P = 0.053);而第3-4周冲击组平均Hb水平比常规组分别高3.8 g/L和3.4 g/L,具有显著性差异(P = 0.048-P = 0.029);至5-6-7-8周时,冲击组虽然平均Hb水平比常规组高,但两者差异不显著(P > 0.05)-冲击组+常规组与对照组相比,从第三周开始平均Hb水平即稳步升高(P < 0.01)-结论:rhEPO能有效治疗肿瘤患者化疗中贫血,保障化疗正常进行-冲击疗法与常规疗法相比,能较快地提高化疗中患者Hb水平,但对后期Hb水平两者差异不大-

    Abstract:

    Objective:To investigate the effect of recombinant human erythropoietin(rhEPO) on the hemoglobin(Hb) levels of anemic malignancy patients receiving chemotherapy. Methods:151 malignancy patients who received chemotherapy were randomly divided into 3 groups: the common therapy group,received rhEPO 10 000 U three times per week for 8 weeks;the high-dose induction therapy group, received rhEPO 20 000 U s.c. per day on d3~d8,and then rhEPO 10 000 U s.c. three times per week;the control group,received other managements similar to rhEPO therapy. Results:The mean Hb level of the high-dose group increased by 2.6 g/L in two weeks with the therapy of rhEPO(P = 0.000),and higher than that of the common therapy group by 2.9 g/L,but there was no statistic significance in Hb between the two groups(P = 0.053); On the 3rd and 4th week,the mean Hb level of high-dose group reached 3.8 g/L and 3.4 g/L, higher than that of the control group(P = 0.048 and 0.029, respectively);the high-dose group, compared with the common group, had a higher level of Hb at the 5 th,6 th,7 th and 8 th week, although they had no statistic difference in Hb levels(P > 0.05). Compared with that of the control group,the mean Hb level of rhEPO therapy group had more steadily increased since the 3rd week(P < 0.01). Conclusion:rhEPO can effectively treat the anemic malignancy patients receiving chemotherapy. Compared with the common therapy,the high-dose therapy can more quickly improve the mean Hb level of malignancy patients, but both of them have no significant difference in later period.

    参考文献
    相似文献
    引证文献
引用本文

沈文香,陈敏斌,沈 刚,周丽娜.重组人促红细胞生成素治疗肿瘤化疗中贫血的临床研究[J].南京医科大学学报(自然科学版),2008,28(8):1054-1057

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期:
  • 出版日期:
通知关闭
郑重声明